A Canadian study evaluated the cost effectiveness of FC plus serum CRP/ESR versus CRP/ESR alone in a hypothetical primary care setting and found that FC was expected to cost more than blood tests alone but overall was likely to be cost effective and reduce the time to IBD diagnosis [107]. The gene discussed is ESR1; the disease is inflammatory bowel disease.